News
Sep 2022
Our technology on using cfDNA methylome to detect cancer has been published in Nature Communications!
News link:
[UCLA News]
[GenomeWeb]
[HemOnc Today]
[ScieneDaily]
[Biocompare]
Sep 2022
EarlyDx has been awarded a NIH SBIR Phase II grant on validating our cfDNA methylome technology for the early detection of liver and lung cancer.
May 2022
EarlyDx announced the appointment of Guanghui Hu as co-CEO.
May 2022
EarlyDx published cfTrack: Non-invasive monitoring of cancer MRD, Recurrence, and Evolution in Clinical Cancer Research.
Sep 2021
EarlyDx Awarded an NIH SBIR Phase I Contract on the Further Development of the Cloud Computing Platform for Liquid Biopsy.
April 2021
Co-founder Jasmine Zhou presented EarlyDx’s CancerRadar Technology and Clinical Data in Oral Presentation at AACR Annual Meeting 2021 on April 10, 2021.
May 2020
EarlyDx Awarded an NIH SBIR Phase I Grant for Assay Development.
Feb 2020
EarlyDx closed $5M Series Seed-1 Fundraising Led by Alpha Edison.
May 2019
EarlyDx Exhibits its One-Stop Shop Bioinformatics Platform, EarlyDx-Cloud, at 2019 ASCO Annual Meeting.